Format

Send to

Choose Destination
Lancet. 2017 Oct 21;390(10105):1888-1917. doi: 10.1016/S0140-6736(17)30788-2. Epub 2017 Apr 20.

Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy.

Author information

1
Department of Medicine, University of British Columbia, Vancouver, BC, Canada. Electronic address: alevin@providencehealth.bc.ca.
2
Department of Medicine, University of Calgary, Calgary, AB, Canada.
3
Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
4
Johns Hopkins University Bloomberg School of Public Health, George W Comstock Center for Public Health Research and Prevention, Baltimore, MD, USA; Johns Hopkins University School of Medicine, Welch Center for Prevention, Epidemiology and Clinical Research, Baltimore, MD, USA.
5
International Society of Nephrology, Brussels, Belgium.
6
Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, TN, USA.
7
Merck Research Laboratories, Boston, MA, USA.
8
Department of Internal Medicine, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
9
Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, Groningen, Netherlands.
10
The George Institute for Global Health, Sydney, NSW, Australia; Concord Repatriation General Hospital, Concord, NSW, Australia.
11
Hennepin County Medical Center, Minneapolis, MN, USA; University of Minnesota, Minneapolis, MN, USA.
12
Division of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany.
13
Department of Internal Medicine and Department of ComputationalMedicine and Bioinformatics, University of Michigan, Ann Arbor, MI, USA.
14
Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA.
15
Institute of Biomedical Ethics and Klinik für Nephrologie University Hospital, University of Zurich, Zurich, Switzerland.
16
Department of Medicine, University of California, San Diego, CA, USA.
17
Department of Internal Medicine and Charles and Jane Pak Center of Mineral Metabolism and Clinical Research, University of Texas Southwestern Medical Center, Dallas, TX, USA.
18
Faculty of Health Sciences, Universidad Panamericana, Mexico City, Mexico.
19
Department of Medicine, University of Alberta, Edmonton, AB, Canada.
20
Program of Applied Translational Research, Department of Medicine, Yale University, New Haven, CT, USA; Veterans Affairs Medical Center, West Haven, CT, USA.
21
The George Institute for Global Health, Sydney, NSW, Australia; University of Sydney, Sydney, NSW, Australia.
22
Kolling Institute of Medical Research, University of Sydney, Sydney, NSW, Australia.
23
Division of Renal Medicine, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
24
Providence Medical Research Center, Providence Health Care Kidney Research Institute, Nephrology Division and Institute for Translational Health Sciences, University of Washington, Spokane, WA, USA.
25
Centre for Nephrology, Royal Free Hospital, University College London, London, UK.
26
Department of Nephrology and Hypertension, University of Erlangen-Nürnberg, Erlangen, Germany.

Abstract

The global nephrology community recognises the need for a cohesive plan to address the problem of chronic kidney disease (CKD). In July, 2016, the International Society of Nephrology hosted a CKD summit of more than 85 people with diverse expertise and professional backgrounds from around the globe. The purpose was to identify and prioritise key activities for the next 5-10 years in the domains of clinical care, research, and advocacy and to create an action plan and performance framework based on ten themes: strengthen CKD surveillance; tackle major risk factors for CKD; reduce acute kidney injury-a special risk factor for CKD; enhance understanding of the genetic causes of CKD; establish better diagnostic methods in CKD; improve understanding of the natural course of CKD; assess and implement established treatment options in patients with CKD; improve management of symptoms and complications of CKD; develop novel therapeutic interventions to slow CKD progression and reduce CKD complications; and increase the quantity and quality of clinical trials in CKD. Each group produced a prioritised list of goals, activities, and a set of key deliverable objectives for each of the themes. The intended users of this action plan are clinicians, patients, scientists, industry partners, governments, and advocacy organisations. Implementation of this integrated comprehensive plan will benefit people who are at risk for or affected by CKD worldwide.

PMID:
28434650
DOI:
10.1016/S0140-6736(17)30788-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center